| 12466822 |
Heterocyclic compounds as immunomodulators |
Neil Lajkiewicz, Chunhong He, Kaijiong Xiao, Weihao Zhu, Zhenzhong Li +3 more |
2025-11-11 |
|
| 12466828 |
Bicyclic amines as CDK2 inhibitors |
Yingda Ye, Zhenzhong Li, Ding-Quan Qian, Sarah Winterton, Kaijiong Xiao +7 more |
2025-11-11 |
|
| 12441731 |
Pyrazolopyrimidine compounds and uses thereof |
Oleg Vechorkin, Minh Tri Nguyen, Changhe Qi, Anlai Wang, Wenqing Yao +1 more |
2025-10-14 |
|
| 12312331 |
Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
Qinda Ye, Jingwei Li, Ken Mukai, Brandon Smith, Wenqing Yao +4 more |
2025-05-27 |
|
| 12247026 |
Heterocyclic compounds as immunomodulators |
Jingwei Li, Wenqing Yao |
2025-03-11 |
|
| 12247038 |
Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
Jingwei Li, Wenqing Yao |
2025-03-11 |
|
| 12187725 |
Tricyclic urea compounds as JAK2 V617F inhibitors |
Yanran Ai, Yu Sheng Bai, Joseph Barbosa, Hao Feng, Leah C. Konkol +5 more |
2025-01-07 |
|
| 12187743 |
Heterocyclic compounds as immunomodulators |
Kaijiong Xiao, Wenqing Yao |
2025-01-07 |
|
| 12129267 |
Heteroaryl amide compounds as sting activators |
Neil Lajkiewicz, Wenqing Yao |
2024-10-29 |
$111,860,000 |
| 12060433 |
CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy |
Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane +9 more |
2024-08-13 |
$73,572,000 |
| 12030889 |
Imidazopyridazine and imidazopyridine compounds and uses thereof |
Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Wenqing Yao |
2024-07-09 |
$15,981,000 |
| 11999740 |
Fused pyrazine derivatives as A2A / A2B inhibitors |
Xiaozhao Wang, Peter Carlsen, Pei Gan, Gia Hoang, Yong Li +3 more |
2024-06-04 |
$26,035,000 |
| 11981671 |
Bicyclic pyrazolyl amines as CDK2 inhibitors |
Joshua Hummel, Jingwei Li, Ding-Quan Qian |
2024-05-14 |
$75,957,000 |
| 11958861 |
Spirocyclic lactams as JAK2 V617F inhibitors |
Stacey Shepard, Charles Cole, Nikoo Falahatpisheh, Kai Liu, Lixin Shao +3 more |
2024-04-16 |
$36,460,000 |
| 11919904 |
Sulfonylamide compounds as CDK2 inhibitors |
Alexander Sokolsky, Sarah Winterton, Wenqing Yao, Min Ye, Yingnan Chen +2 more |
2024-03-05 |
$19,783,000 |
| 11919908 |
Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
Andrew W. Buesking, Onur Atasoylu, Cheng-Tsung Lai, Padmaja Polam, Wenqing Yao |
2024-03-05 |
$19,783,000 |
| 11912722 |
Tricyclic heteroaryl compounds as sting activators |
Yingda Ye, Wenqing Yao |
2024-02-27 |
$75,873,000 |
| 11873309 |
Heterocyclic compounds as immunomodulators |
Kaijiong Xiao, Fenglei Zhang, Wenqing Yao |
2024-01-16 |
$40,689,000 |
| 11873304 |
Fused pyrimidine derivatives as A2A/A2B inhibitors |
Xiaozhao Wang, Heeoon Han, Matthew S. McCammant, Wenqing Yao, Zhiyong Yu +1 more |
2024-01-16 |
$40,689,000 |
| 11866435 |
Heterocyclic compounds as immunomodulators |
Neil Lajkiewicz, Wenqing Yao |
2024-01-09 |
$16,368,000 |
| 11866432 |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
Alexander Sokolsky, Wenqing Yao |
2024-01-09 |
$16,368,000 |
| 11851426 |
Bicyclic amines as CDK2 inhibitors |
Yingda Ye, Zhenwu Li, Ding-Quan Qian, Sarah Winterton, Wenqing Yao |
2023-12-26 |
$41,326,000 |
| 11840546 |
Imidazopyridazine compounds and uses thereof |
Jun Pan, Yu Sheng Bai, Wenqing Yao |
2023-12-12 |
$44,258,000 |
| 11840534 |
Substituted tricyclic compounds as FGFR inhibitors |
Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao |
2023-12-12 |
$44,258,000 |
| 11787793 |
Heterocyclic compounds as immunomodulators |
Jingwei Li, Wenqing Yao |
2023-10-17 |
$36,527,000 |